Already approved in later stage and high-risk cHL, the goal of ongoing Adcetris studies is to “develop curative treatments that improve survival while also reducing toxicity,” Jeremy Abramson, director of the Jon and Jo Ann Hagler Center for Lymphoma at Massachusetts General Hospital and principal investigator for the Phase II trial, said in a statement.
Following its failed deal with Merck last year, Seagen has a new suitor. The Seattle-based company is in talks with Pfizer over a potential acquisition, The Wall Street Journal reported Sunday evening, citing people familiar with the matter.
Seagen is on a roll this week. After naming David R. Epstein as its new CEO, the Washington-based biotech announced that Adcetris (brentuximab vedotin) has been given FDA approval for the treatment of children aged two years and above with high-risk classical Hodgkin lymphoma.